Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of cancer-related fatigue in multiple myeloma patients

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Cancer-related fatigue (CRF) is one of the adverse events in multiple myeloma (MM) patients treated with cytotoxic agents, proteasome inhibitors (PIs), and immunomodulatory drugs (IMiDs) such as bortezomib, lenalidomide, and thalidomide. The aims of our study were to prospectively analyze the clinical significance of CRF, and to evaluate the cumulative incidence of CRF and the survival rates of 16 MM patients who were treated with PIs and IMiDs. Reactivation of salivary human herpes virus (HHV)-6 and HHV-7 was analyzed using real-time quantitative polymerase chain reaction (qPCR). CRF was evaluated using a visual analog scale (VAS). Eleven newly diagnosed multiple myeloma (NDMM) and five relapsed or refractory MM patients were enrolled in this study. The cumulative incidence of CRF was 54.9%. The treatment types were not associated with the CRF incidence. The cumulative incidence of reactivation of HHV-6 and HHV-7 was 73.1% and 45.6%, respectively. However, the reactivation of HHV-6 and HHV-7 was not related to CRF. The overall survival (OS) and progression-free survival (PFS) in NDMM patients with CRF was significantly shorter than in those without CRF. In conclusion, CRF was one of the major symptoms in MM patients, and predicted shorter OS and PFS in NDMM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Saligan LN, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S, et al. The biology of cancer-related fatigue: a review of the literature. Support Care Cancer. 2015;23:2461–78.

    Article  Google Scholar 

  2. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98:2992–8.

    Article  CAS  Google Scholar 

  3. MillsKH CawleyJC. Abnormal monoclonalantibody-defined helper/ suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol. 1983;53:271–5.

    Article  Google Scholar 

  4. Ogawara H, Handa H, Yamazaki T, Toda T, Yoshida K, Nishimoto N, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res. 2005;29:135–40.

    Article  CAS  Google Scholar 

  5. Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015;5:e306.

    Article  CAS  Google Scholar 

  6. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621–9.

    Article  CAS  Google Scholar 

  7. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–40.

    Article  Google Scholar 

  8. Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohno K, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2006;193:68–79.

    Article  CAS  Google Scholar 

  9. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1031–7.

    Article  Google Scholar 

  10. Zerr DM. Human herpesvirus 6 (HHV-6) disease in the setting of transplantation. Curr Opin Infect Dis. 2012;25:438–44.

    Article  CAS  Google Scholar 

  11. Aoki R, Kobayashi N, Suzuki G, Kuratsune H, Shimada K, Oka N, et al. Human herpesvirus 6 and 7 are biomarkers for fatigue, which distinguish between physiological fatigue and pathological fatigue. Biochem Biophys Res Commun. 2016;478:424–30.

    Article  CAS  Google Scholar 

  12. Blesch KS, Paice JA, Wickham R, Harte N, Schnoor DK, Purl S, et al. Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum. 1991;18:81–7.

    CAS  PubMed  Google Scholar 

  13. Gift AG. Visual analogue scales: Measurement of subjective phenomena. Nurs Res. 1989;38:286–8.

    Article  CAS  Google Scholar 

  14. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  Google Scholar 

  15. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.

    Article  Google Scholar 

  16. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, Fillet AM, Mangeney N, Vidaud M, et al. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J Virol Methods. 2002;100:27–35.

    Article  CAS  Google Scholar 

  17. Hara S, Kimura H, Hoshino Y, Tanaka N, Nishikawa K, Ihira M, et al. Detection of herpesvirus DNA in the serum of immunocompetent children. Microbiol Immunol. 2002;46:177–80.

    Article  CAS  Google Scholar 

  18. Kanda Y. Investigation of the freely-available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  19. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    Article  Google Scholar 

  20. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Standtmauer EA, et al. Long-term follow-up on overall survival from MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–52.

    Article  CAS  Google Scholar 

  21. Paiva CE, Paiva BS. Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers. Support Care Cancer. 2013;21:1053–60.

    Article  Google Scholar 

  22. Orre IJ, Murison R, Dahl AA, Ueland T, Aukrust P, Fosså SD. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun. 2009;23:868–74.

    Article  CAS  Google Scholar 

  23. de Raaf PJ, Sleijfer S, Lamers CH, Jager A, Gratama JW, van der Rijt CC. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer. 2012;118:6005–11.

    Article  Google Scholar 

  24. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clinic Proc. 1975;50:29–40.

    CAS  Google Scholar 

  25. Riccardi A, Gobbi PG, Ucci G, Bertoloni D, Luoni R, Rutiqliano L, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27:1401–5.

    Article  CAS  Google Scholar 

  26. Musto P, Falcone A, D’Arena G, Scalzulli PR, Matera R, Minevini MM, et al. Clinical recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokine and monitoring of erythropoiesis. Eur J Haematol. 1997;58:314–9.

    Article  CAS  Google Scholar 

  27. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–98.

    Article  CAS  Google Scholar 

  28. Okuyama T, Akechi T, Kugaya A, Okamura H, Imoto S, Nakano T, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer. 2000;8:215–222.

    Article  Google Scholar 

  29. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–96.

    Article  CAS  Google Scholar 

  30. Fagundes CP, Glaser R, Alfano CM, Bennett JM, Povoski SP, Lipari AM, et al. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immunol. 2012;26:394–400.

    Article  Google Scholar 

  31. Nefzi F, Ben Salem NA, Khelif A, Feki S, Aouni M, Gautheret-Dejean A. Quantitative analysis of human herpesvirus-6 and human cytomegalovirus in blood and saliva from patients with acute leukemia. J Med Virol. 2014;87:451–60.

    Article  Google Scholar 

  32. Gautheret-Dejean A, Aubin JT, Poirel L, Nicolas JC, Rozenbaum W, Agut H. Detection of human Betaherpesvirinae in saliva and urine from immunocompromised and immunocompetent subjects. J Clin Microbiol. 1997;35:1600–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Nucci M, Anaisseie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25.

    Article  CAS  Google Scholar 

  34. San Miguel JF, Sclag R, Khuageva NK, Dimopoulos MA, Shpiberg O, Kropff M, et al. Bortezomib plus melphalan and predonisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.

    Article  CAS  Google Scholar 

  35. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784–90.

    Article  CAS  Google Scholar 

  36. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107:3575–83.

    Article  CAS  Google Scholar 

  37. Ljungman P, Dahl H, Xu YH, Larsson K, Brytting M, Linde A. Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant. 2007;39:497–9.

    Article  CAS  Google Scholar 

  38. Ogata M, Satou T, Kadota J, Saito N, Yoshida T, Okumura H, et al. Human Herpesvirus 6 (HHV-6) Reactivation and HHV-6 Encephalopalitis After Allogeneic Hematopoietic Cell Transplantation: A Multicenter, Prospective Study. Clin Infect Dis. 2013;57:671–81.

    Article  Google Scholar 

  39. Ogata M, Satou T, Kawano R, Yoshikawa T, Ikewaki J, Kohno K, et al. High Incidence of Cytomegalovirus, Human Herpesvirus-6, and Epstein-Barr Virus Reactivation in Patients Receiving Cytotoxic Chemotherapy for Adult T Cell Leukemia. J Med Virol. 2011;83:702–9.

    Article  Google Scholar 

  40. Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol. 2013;85:2101–9.

    Article  CAS  Google Scholar 

  41. Catania G, Bell C, Ottonelli S, Marchetti M, Bryce J, Grossi A, et al. Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI). Support Care Cancer. 2013;21:413–9.

    Article  Google Scholar 

  42. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

    Article  CAS  Google Scholar 

  43. Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank our attending doctors, dedicated fellows, and nurses at the Jikei University School of Medicine. In addition, we appreciate laboratory technicians of Department of Virology. And we offer special thanks to our MM patients and their families.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan

    Kazuhito Suzuki, Takaki Shimada, Yuichi Yahagi, Katsuki Sugiyama, Shinobu Takahara, Takeshi Saito, Jiro Minami, Hiroki Yokoyama, Yutaro Kamiyama, Atsushi Katsube, Keisuke Aiba & Shingo Yano

  2. Department of Virology, The Jikei University School of Medicine, Tokyo, Japan

    Nobuyuki Kobayashi & Kazuhiro Kondo

  3. Central Clinical Laboratory, The Jikei University Hospital, Tokyo, Japan

    Yoji Ogasawara

  4. Department of Public Health and Enviromental Medicine, The Jikei University School of Medicine, Tokyo, Japan

    Hiroyuki Yanagisawa

Authors
  1. Kazuhito Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoji Ogasawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichi Yahagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsuki Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinobu Takahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jiro Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroki Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yutaro Kamiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Atsushi Katsube
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuhiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroyuki Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Keisuke Aiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shingo Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhito Suzuki.

Ethics declarations

Conflict of interest

K.K. has submitted a patent application entitled “Methods for Assessing Fatigue Level and Applications Thereof” US patent application publication 2008/0280283 A1. K.K. has stock in Virus Ikagaku Kenkyusho Inc. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities (Grant number S1201032); Virus Ikagaku Kenkyusho Inc. The other authors indicated no potential conflicts of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, K., Kobayashi, N., Ogasawara, Y. et al. Clinical significance of cancer-related fatigue in multiple myeloma patients. Int J Hematol 108, 580–587 (2018). https://doi.org/10.1007/s12185-018-2516-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-2516-1

Keywords

Search

Navigation